The thesis
momentum-code runs a simple, legible premise: buy the top positive movers in a fixed universe, capped per position. The universe is 24 US large-caps — mega-cap tech (AAPL, MSFT, NVDA, GOOGL), financials (JPM, BAC, V, MA), healthcare (JNJ, UNH, PFE, ABBV), staples and industrials (PG, KO, WMT, COST, CAT, HON), and energy (XOM, CVX). No exotic instruments, no leverage in the description. The appeal is transparency; the risk is that plain-vanilla momentum on a crowded large-cap set offers little edge others haven't already arbitraged.
Backtest performance
Over 451 days the strategy returned 19.76% (final equity $11,976), a 10.6% CAGR. That headline is respectable, but the quality metrics are more sober: a Sharpe of 0.65 and a max drawdown of 20.48% — a drawdown roughly equal to the entire annualised return, which is a poor return-to-pain ratio. Turnover of 92.74% across just 5 trades and $5 total fees confirms this is a concentrated, low-frequency book rather than an active trader. The reported 0% win rate almost certainly reflects unclosed round-trips rather than five losing bets, but it's a reminder that the sample is thin.
Validation
The walk-forward picture is genuinely encouraging: all 4 folds were positive (15.38%, 3.27%, 12.18%, 13.71%), with out-of-sample return of 13.71% and an OOS Sharpe of 1.93. Fold-level Sharpes reached 2.31–2.47 in the strong windows. So why did validation fail?
The answer is in the deflated statistics. Against 6 trials, the Deflated Sharpe Ratio is just 0.338 — below the confidence threshold — even though the raw Probabilistic Sharpe Ratio (0.811) looks fine. In plain terms: once you penalise for how many variants were tried and for the modest full-sample Sharpe (0.648), the evidence that this edge is real rather than lucky is not strong enough to clear the gate. That is the validation layer doing exactly its job — resisting an overfit-friendly narrative that four green folds would otherwise sell.
Recent activity — a stalled book
Here the concern sharpens. The last executed trades date to late May and June 1 (XOM, NVDA, BAC, HON, MSFT). Every scheduled run since — six sessions from Sep 17 to Sep 25 — reports 0 executed, 2–3 rejected, with cash frozen at $608.79 and total value drifting between roughly $10,316 and $10,400. The strategy is live in name but effectively dormant: it is generating candidates and rejecting all of them, likely on position caps or insufficient cash.
Verdict
momentum-code is a clean, interpretable strategy with a credible walk-forward record but two honest red flags: a failed statistical gate that says the edge may be noise, and a live book that hasn't transacted in months. Strengths — positive across every fold, low fees, understandable logic. Risks — sub-1 full-sample Sharpe, a 20% drawdown, a five-trade sample too small to trust, and an execution pipeline that is currently doing nothing but rejecting orders. Worth watching; not yet worth conviction.